April 7, 2022
Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: ReViral
April 8, 2019
ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme
Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended) The…